Advancing Synovial Sarcoma Care: Exploring Innovations in Targeted Therapies - Episode 16
A panelist discusses how T-cell receptor (TCR) therapies are likely to evolve through innovations such as allogeneic approaches, enhanced manufacturing processes, identification of new target antigens, and potential combinations with other immunotherapies, which could expand their applicability across multiple sarcoma subtypes and other solid tumors while improving accessibility and efficacy.
Video content above is prompted by the following:
How do you see the future of TCR therapies evolving for sarcomas and other solid tumors?